Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework

BACKGROUND: Use of combinations of long-acting β(2) agonists/long-acting muscarinic antagonists (LABA/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is increasing. Nevertheless, existing evidence on cardiovascular risk associated with LABA/LAMA versus another dual combination, L...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chun-Yu, Pan, Sheng-Wei, Hsu, Chia-Chen, Liu, Jason J., Kumamaru, Hiraku, Dong, Yaa-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543303/
https://www.ncbi.nlm.nih.gov/pubmed/37775734
http://dx.doi.org/10.1186/s12931-023-02545-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543303/
https://www.ncbi.nlm.nih.gov/pubmed/37775734
http://dx.doi.org/10.1186/s12931-023-02545-9

Ejemplares similares